A Phase 1 Study of Topotecan Liposomes Injection (TLI) in Subjects With Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors.

Trial Profile

A Phase 1 Study of Topotecan Liposomes Injection (TLI) in Subjects With Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Topotecan (Primary)
  • Indications Ovarian cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Spectrum Pharmaceuticals; Talon Therapeutics
  • Most Recent Events

    • 16 Oct 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2018.
    • 16 Oct 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2018.
    • 16 Jun 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top